Recent results have shown that genetically driven PD-L1 expression and MHC class II positivity on HRS cells in cHL, rather than MHC class I expression, are potential predictors of favorable outcome after PD-1 blockade15. Here, PDCD1 is linked to classic Hodgkin lymphoma.